Tradestie Institutional Equity Comparison Engine
ABUS vs YQQQ โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABUS Overall Edge
ABUS Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arbutus Biopharma Corporation Common Stock (ABUS) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ABUS trades at 10.2x Forward P/E with 80.1% operating margin (-43.5% YoY revenue) versus YQQQ at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ABUS sits in CONSOLIDATION (28th %ile IV; Dealer Gamma Walls on Pro) against YQQQ sits in UNCLASSIFIED (13th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
ABUS
ABUS 10.2x vs YQQQ N/M Fwd P/E
Growth & Margin Winner
ABUS
Op Margin 80.1% vs N/A ยท YoY -43.5% vs N/A
Momentum & Technical Winner
ABUS
1Y -11.4% vs -20.6% ยท 52W Pos 28% vs 17%
Options & Structure Winner
ABUS
CONSOLIDATION (28th %ile IV) vs UNCLASSIFIED (13th %ile IV)
ABUS
NASDAQ
Arbutus Biopharma Corporation Common Stock
Pharmaceutical Preparations
$4.04
-1.22% 1D
Market Cap
$627.0M
1M Return
-4.27%
1Y Return
-11.4%
Forward P/E
10.2x
Unified AI Score
56.7 / 100
HOLD
Tech 73.0
Fund 66.0
Flow 68.0
Mom 53.7
YQQQ
NASDAQ
YieldMax Short N100 Option Income Strategy ETF
Institutional Equity
$9.84
+2.1% 1D
Market Cap
N/A
1M Return
+2.59%
1Y Return
-20.65%
Forward P/E
N/M
Unified AI Score
50.6 / 100
HOLD
Tech 58.0
Fund 55.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ABUS -11.4%
YQQQ -20.65%
Spread: +9.25 pp (ABUS Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ABUS TTM Op. Margin: 80.1%
YQQQ TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABUS vs YQQQ. Trailing 12-month operating profitability (ABUS 80.1% vs YQQQ N/A) and valuation multiples (ABUS 10.2x vs YQQQ N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ABUS | YQQQ | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $627.0M | N/A | Larger Scale | ABUS |
| Trailing P/E Ratio Valuation | 3.6x | N/M | Lower Multiple | ABUS |
| Forward P/E Ratio Valuation | 10.2x | N/M | Lower Multiple | ABUS |
| Revenue Growth (YoY) Growth | -43.5% | N/A | Higher Growth | ABUS |
| Operating Margin (TTM) Profitability | 80.1% | N/A | Higher Margin | ABUS |
| Net Profit Margin Profitability | 121.2% | N/A | Higher Margin | ABUS |
| Return on Equity (ROE) Capital Efficiency | 269.6% | N/A | Higher ROE | ABUS |
| 52-Week Range Position Momentum | 28% ($4โ$5) | 17% ($9โ$13) | Stronger Trend | ABUS |
| Beta / 30D Volatility Risk Regime | 1.20ฮฒ ยท 51% Vol | -1.10ฮฒ ยท 27% Vol | Lower Realized Risk | YQQQ |
| Unified Institutional Score Composite Signal | 56.7 / 100 (HOLD) | 50.6 / 100 (HOLD) | Higher Composite | ABUS |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ABUS vs YQQQ Buy Guide
ABUS
CONSOLIDATION
92d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
28th %ile
IV Regime
Balanced (25thโ60th %ile)
YQQQ
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
13th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ABUS nor YQQQ registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.